NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment by Casey, Jillian P. et al.
1Scientific RepoRts | 5:16022 | DOi: 10.1038/srep16022
www.nature.com/scientificreports
NAA10 mutation causing a novel 
intellectual disability syndrome 
with Long QT due to N-terminal 
acetyltransferase impairment
Jillian P. Casey1,2, Svein I. Støve3, Catherine McGorrian4,5, Joseph Galvin4, Marina Blenski3, 
Aimee Dunne2, Sean Ennis2, Francesca Brett6, Mary D. King2,7, Thomas Arnesen3,8 & 
Sally Ann Lynch1,2,9
We report two brothers from a non-consanguineous Irish family presenting with a novel syndrome 
characterised by intellectual disability, facial dysmorphism, scoliosis and long QT. Their mother has 
a milder phenotype including long QT. X-linked inheritance was suspected. Whole exome sequencing 
identified a novel missense variant (c.128 A > C; p.Tyr43Ser) in NAA10 (X chromosome) as the cause 
of the family’s disorder. Sanger sequencing confirmed that the mutation arose de novo in the carrier 
mother. NAA10 encodes the catalytic subunit of the major human N-terminal acetylation complex 
NatA. In vitro assays for the p.Tyr43Ser mutant enzyme showed a significant decrease in catalytic 
activity and reduced stability compared to wild-type Naa10 protein. NAA10 has previously been 
associated with Ogden syndrome, Lenz microphthalmia syndrome and non-syndromic developmental 
delay. Our findings expand the clinical spectrum of NAA10 and suggest that the proposed correlation 
between mutant Naa10 enzyme activity and phenotype severity is more complex than anticipated; 
the p.Tyr43Ser mutant enzyme has less catalytic activity than the p.Ser37Pro mutant associated with 
lethal Ogden syndrome but results in a milder phenotype. Importantly, we highlight the need for 
cardiac assessment in males and females with NAA10 variants as both patients and carriers can have 
long QT.
N-terminal (Nt-) acetylation is one of the most common protein modifications in eukaryotes1. While 
its existence has been known for many years, the exact biological role of Nt-acetylation is still unclear. 
Early evidence suggested that Nt-acetylation may confer protection against protein degradation2. More 
recently, Nt-acetylation has been shown to act as a degradation signal to regulate protein complex stoi-
chiometries3,4, protein complex formation5, subcellular targeting6–8 and protein folding9. It is likely that 
the physiological role of Nt-acetylation differs depending on the protein substrate. In humans, six NATs 
have been identified (NatA-NatF)10. NatA is the major NAT complex and modifies approximately 40% 
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of all human proteins1. NatA comprises a catalytic subunit encoded by NAA10 (ARD1) and an auxiliary 
subunit encoded by NAA15 (NAT1/NATH)11,12.
The first reported NAT gene linked to human disease was NAA10. In 2011, Rope and colleagues 
showed that missense mutations in exon 2 of NAA10 caused Ogden syndrome13. Ogden syndrome is 
a rare perinatal lethal disorder characterised by global developmental delay, craniofacial abnormalities, 
hypotonia, cardiac arrhythmia and an aged appearance with lax skin13. Three years later, Esmailpour 
and colleagues reported a splice mutation in intron 7 of NAA10 as the cause of Lenz microphthalmia 
syndrome (LMS) which includes eye malformations, mild to severe developmental delay and defects in 
the skeletal and genitourinary systems14. That same year, de novo mutations in exons 5 and 6 were shown 
to cause severe non-syndromic developmental delay in an unrelated male and female child15. This was 
the first time that a female with an NAA10 mutation was shown to have a fully penetrant and severe 
phenotype. The overlapping but diverse phenotypes associated with NAA10 were proposed to be allelic 
disorders with a correlation between the level of remaining Naa10 enzymatic activity and phenotype 
severity14.
We report on two affected brothers from a non-consanguineous Irish family presenting with an 
intellectual disability syndrome with facial dysmorphism, hypotonia, scoliosis and long QT (Fig. 1 and 
Table  1). Their mother is also mildly affected suggesting the possibility of X-linked inheritance. More 
than 100 genes on the X chromosome have been associated with disorders that include X-linked intel-
lectual disability (XLID) as part of the clinical presentation16. After negative single gene testing, whole 
exome sequencing was undertaken to try and establish the genetic cause of the syndrome in this family. 
We identified a novel variant in NAA10 (X chromosome) as the cause of this previously unreported 
syndrome, expanding the clinical spectrum associated with NAA10 mutation. Functional studies showed 
reduced acetylation activity of the mutant Naa10 enzyme implicating altered Nt-acetylation as one of the 
mechanisms contributing to the pathogenesis of syndromic intellectual disability.
Results
Clinical report: Patient III:1. Patient III:1 was born at term. Perinatal history was unremarkable. 
He had jaundice and congenital pneumonia in the newborn period and was found to have an innocent 
heart murmur. Patient III:1 was first noted to have problems in the first year of life when he showed poor 
weight gain and delay in sitting and standing. Failure to thrive persisted and he continued to grow less 
than the 3rd centile for height, weight and head circumference. Subsequent investigations identified bilat-
eral acetabular dysplasia which was treated with splints. He took his first step at 23 months and walked at 
27 months. Speech was also significantly delayed; he first started using long sentences at 3.5 years. At age 
4 years, he showed deterioration in his gait with marked waddling and a persisting tendency to favour 
Figure 1. Patient photographs. (A–F) Photograph of patient III:1 and III:2 respectively showing (A,D) 
coarse features, depressed midface, hypertelorism, upward tufting or horizontal eyebrows, low set ears, 
coarse hair, (B,E) profile, and (C,F) broad teeth.
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his right lower limb. He also had valgus deformity of both heels. Physical examination at 5 years of age 
identified prominent dysmorphic and coarse features (Fig. 1A–C and Table 1).
Patient III:1 was extensively investigated including evaluation for amino and organic acidopathy, 
mucopolysarcoidosis, lysosomal storage diseases and liver dysfunction, all of which were negative. 
Karyotyping of the blood and fibroblasts showed a normal 46 XY karyotype. Cranial nerve examination 
and fundoscopy were normal and there was no evidence of appendicular ataxia. Computed tomog-
raphy (CT) showed mild dilation of the lateral ventricles including the temporal horns. The sylvian 
fissures were a little prominent. There was no focal abnormality or evidence of a white matter disorder. 
Clinical feature III:1 III:2 II:2 (mother)
Neonatal jaundice yes yes not known
Growth parameters height < 0.4
thct, weight < 0.4thct, 
OFHC < 3rdct
height 25thct, weight < 25thct, OFHC 
91stct, height 10
th ct
Intellectual disability moderate mild Mild
Facial
 Dysmorphism
coarse features, low anterior headline 
coming to a peak in the midline, 
hypertelorism, epicanthic folds, 
prominent philtrum and forehead with 
high cheek bones, depressed mid face, 
snub nose, flat nasal bridge, low set 
and small crumpled ears, coarse hair
similar dysmorphic features to brother 
III:1 with mild posterior rotation of ears
similar facial features 
to her sons; small ears, 
coarse hair
 Grommet insertion and adeno/
tonsillectomy yes (age 3.5 years) yes (age 2 years) no
 Eye morphology normal Normal Normal
 Eye anomalies not tested moderate RCS, HA, dense RA Normal
 Hypertelorism yes no No
 Eyebrows pointy, upward tufting horizontal Normal
 Downslanting palpebral fissures yes, epicanthic folds yes Yes
 Skeletal
 Syndactyly 2/3 toe syndactyly no no
 Scoliosis mild; lower spine right lumbar no
 Abnormal teeth broad front teeth, hyper -calcification 6 lower broad front teeth broad front teeth
 Small hands/feet yes; shoe size 38 yes; shoe size 38 yes; size 37.5
 Feet abnormalities VD of both heels no no
 Hips marked BAD BAD, PO no
 Inguinal hernia yes yes no
Cardiac
 Arrhythmias yes; two MI yes yes
 Prolonged QT interval yes yes yes
 Other cardiac features innocent HM at birth innocent HM, VT, superior axis ECG premature CAD, VT
Neurological
 Hypotonia yes yes; progressive muscle weakness, poor muscle bulk, mild left HP no
 Seizures yes no no
 MRI mild dilation of LV, mild CA, prominent SF mild dilation of LV, mild CA not tested
 Other features
congenital pneumonia, sacral dimple, 
markedly distended veins over chest 
and upper abdomen, remarkably 
prominent vascular pattern over skull
distended veins on chest, upper 
abdomen and around nipples, long 
history of perennial rhinitis, recurrent 
sinusitis with extensive nasal polyps and 
spasmodic cough
coeliac disease from 
childhood, type 2 
diabetes, Graves disease
Table 1.  Clinical features in Irish family with X-linked intellectual disability syndrome. Patients III:1 
and III:2 are brothers who presented with a developmental delay syndrome and long QT. Their mother 
(II:2) is also mildly affected. Abbreviations: BAD: bilateral acetabular dysplasia; CA: cerebral atrophy; CAD: 
coronary artery disease; HA: hyperopic astigmatism; HM: heart murmur; HP: hemiparesis; LV: lateral 
ventricles; MI: myocardial infarctions; PO: pelvic obliquity; RA: right amblyopia; RCS: right convergent 
squint; SF: sylvian fissures; VD: valgus deformity; VT: ventricular tachycardia.
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Radiosensitivity testing for ataxia telangiectasia was normal, as was chest X-ray and abdominal ultra-
sound. He had a normal cardiology exam aged 4 years but electrocardiogram (ECG) was not performed.
At 7 years of age, patient III:1 had three episodes of collapse and loss of consciousness lasting less 
than 5 minutes. Electroencephalogram (EEG) was abnormal showing mid-line spikes with spread to the 
right parietal region, consistent with an epileptic focus in that location. The overall background of the 
EEG was diffusely slow and disorganised, consistent with an encephalopathy.
Patient III:1 came to the attention of the adult cardiology services aged 22 years, when he suffered an 
out-of-hospital ventricular fibrillation cardiac arrest, which was promptly resuscitated. After recovery, an 
abnormal ECG was noted with atrial fibrillation, lateral T-wave inversion and repolarisation delay and a 
QTc of 515 ms. He reverted to sinus rhythm spontaneously but the QT prolongation persisted. Cardiac 
magnetic resonance imaging (MRI) showed mild concentric left ventricular hypertrophy up to 15 mm, 
with normal left ventricular function. Beta blockers were commenced and an implantable cardiac defi-
brillator (ICD) was sited. The patient received an appropriate ICD discharge age 25 years for an episode 
of sustained polymorphic ventricular tachycardia. Routine ECG age 25 years showed persistence of long 
QT at 533 ms (Fig. 2A).
Clinical report: Patient III:2. Patient III:2 was born by Caesarean section for breech at 35 weeks 
gestation. Similar to his older brother, he had pneumonia, jaundice and failure to thrive in the neonatal 
period. His facial dysmorphism was identical to that of his older brother but he had additional ophthal-
mic anomalies (Fig. 1D–F and Table 1). At 8 months of age he presented with acetabular dysplasia and 
was delayed in sitting, standing and walking. He walked at 27 months and first used meaningful words 
at 2 years of age. Initially, his gait was normal but by 3.5 years he started to show the same waddling gait 
as his brother. He was also later found to have lumbar scoliosis, pelvic obliquity, a left-sided inguinal 
hernia and significantly reduced pulmonary function (likely secondary to muscle weakness and scolio-
sis). Subsequent history included poor feeding and difficulties with swallowing, recurrent diarrhoea and 
Figure 2. ECG and muscle biopsy. (A) Routine ECG on Patient III:1 three years after his presentation 
with an out-of-hospital cardiac arrest. Left ventricular hypertrophy by voltage criteria with lateral T wave 
changes are noted, as well as broad-based QT prolongation with a QTc of 533ms (using Bazett’s formula for 
correction). (B) Haematoxylin and eosin (x 40) staining of muscle biopsy from patient III:2 showed variation 
in fibre size with atrophic fibres. (C) Muscle biopsy from patient III:2 showed random atrophic fibers with 
scattered perivascular lymphocytes. Immunohistochemistry showed that the atrophic fibers were type II with 
type I fiber predominance.
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severe weight loss. His functioning has deteriorated over time with increasing muscle weakness, poor 
muscle bulk, respiratory difficulties, decreased exercise tolerance and evidence of mild left hemiparesis.
Neurological examination aged 3 showed normal cranial nerves and fundi but detected proximal 
weakness of the lower limbs (without spasticity). There was some limitation of abduction of the hips 
bilaterally which may have been related to a problem with muscle contracture. However, tone appeared 
normal and deep tendon reflexes were present symmetrically. MRI brain showed mild dilation of the 
ventricles and Magnetic Resonance Spectroscopy (MRS) brain was normal. Electrophysiology examina-
tion at 15 years of age showed a complex abnormality with widespread, but not universal, evidence of 
a membranopathy suggestive of a true myotonia. Motor and sensory nerve conduction velocities were 
normal as was serum creatine kinase.
Cardiology examination showed a structurally normal heart. However, an ECG identified a superior 
axis and an RSR pattern in V1. Left ventricular function was normal. A repeat ECG at 17 years of age 
showed no abnormalities. At 16 years of age, patient III:2 was admitted to hospital with an acute onset of 
dyspnoea and respiratory distress associated with fever. At 20 years of age, the patient continues to suffer 
from dyspnoea and bronchospasm, requiring bronchodilators. He has no history of syncope, however his 
ECG shows conduction system changes with PR prolongation and lateral T wave flattening, with a QTc of 
494 ms. He has had no documented ventricular arrhythmia on Holter. No cardiomyopathic changes were 
appreciated on transthoracic echo or cardiac MRI. With the finding of QT prolongation, beta blockade 
was added and an implantable loop recorder was sited to monitor for arrhythmia. Rare short runs of 
atrial fibrillation have been detected on this recorder, though no ventricular arrhythmias to date.
Muscle biopsy showed a striking predominance of type I fibres with rare atrophic type I and type 
II fibres (Fig. 2B,C). Small fibres were noted to be randomly scattered throughout the muscle fascicles 
and there were rare perivascular lymphocytes. Ragged red fibres and nemaline rods were not present. 
Ultrastructural examination of the muscle biopsy revealed a striking increase in the number of subsarco-
lemmal mitochondria, large clusters of subsarcolemmal mitochondria and dilatation of the sarcoplasmic 
tubules. Fibroblast culture showed normal fatty acid oxidation and excluded carnitine palmitoyltrans-
ferase II deficiency.
Clinical report: Mother II:2. Individual II:2 has similar facial features to her sons and a mild learn-
ing disability, more evident when compared to unaffected family members (Table 1). At the age of 40, 
she presented with complaints of chest pain and dyspnoea on exertion. She was found to have dyslip-
idaemia and was known at that time to have hypertension. Coronary angiography revealed premature 
coronary artery disease, and she subsequently required a number of coronary angioplasty procedures. 
ECG abnormalities were noted since age 40, with lateral T wave repolarisation changes. Antiplatelet 
agents were added to her list of therapies. Aged 42, the patient experienced a sudden collapse with loss 
of consciousness while still on her usual cardiac medications, including a beta blocker. She was again 
treated with coronary stenting, and a CT brain showed extensive involutional changes. Subsequently, a 
run of monomorphic ventricular tachycardia was observed on a Holter monitor, and her beta blocker 
was changed to bisoprolol. She was diagnosed with Type 2 Diabetes Mellitus aged 44 years. At age 48, 
her ECGs and treadmill ECGs were repeated after the cardiac events which had occurred in her son, and 
QT prolongation was appreciated, with QTc intervals observed between 460 and 500 ms. Given that her 
collapse and her non-sustained ventricular tachycardia were seen in the setting of beta blocker use, an 
ICD was sited (age 48), with no appropriate ICD discharges to date.
Whole exome sequencing. Whole exome sequencing was performed for one affected child (III:2) 
and identified 7 novel or rare hemizygous X chromosome variants that were not present in dbSNP, 
1000 Genomes, the NHLBI EVS database or our 60 Irish control exomes (Table S1). Three variants 
were located within genes previously implicated in developmental delay or intellectual disability; a mis-
sense variant (rs150861758) in SHROOM4 (NM_020717.3; c.1879 C > T; p.(Pro627Ser)), a rare missense 
variant (rs140976011) in ZCCHC12 (NM_173798.2; c.722 G > C; p.(Arg241Thr)) and a novel missense 
variant in NAA10 (NM_001256120.1; c.128 A > C; p.(Tyr43Ser)). SHROOM4 has been associated with 
Stocco Dos Santos syndrome (MIM #300434), a disorder characterised by severe mental retardation, 
delayed/absent speech, short stature, seizures, hyperactivity and aggressive behaviour17. The SHROOM4 
p.(Pro627Ser) is a recurrent variant previously identified in families with X-linked mental retardation 
(XLMR) through exome or panel sequencing18,19. It is suspected to be benign as segregation analyses have 
shown that unaffected family members often carry this variant18. ZCCHC12 has been implicated as an 
XLMR candidate gene and a neurocognitive functional modifier20. NAA10 encodes an N-terminal acet-
yltransferase associated with variable phenotypes including Ogden syndrome, LMS and non-syndromic 
developmental delay13–15. Of note, the involvement of all three genes in monogenic X-linked intellectual 
disability (XLID) has recently been challenged. Piton and colleagues concluded that the role of ZCCHC12 
in XLID is questionable while SHROOM4 and NAA10 require further confirmatory studies21.
Validation and segregation analyses. Sanger sequence analysis of DNA from all available family 
members excluded SHROOM4 and ZCCHC12 as both variants were present in healthy family mem-
bers (data not shown). Only the novel variant in NAA10 segregated with the phenotype in a manner 
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consistent with X-linked recessive inheritance; both of the affected males are hemizygous while their 
mildly affected mother is a heterozygous carrier (Fig.  3). X-inactivation studies in the carrier mother 
showed a normal non-skewed (random) inactivation pattern in blood. To determine whether the NAA10 
c.128 A > C variant was de novo or inherited in the mother (II:2), we sought to sequence the boy’s mater-
nal grandparents (I:1 and I:2). Sanger sequencing confirmed that the maternal grandmother (I:2) did not 
carry the NAA10 variant. However, DNA was unavailable from the maternal grandfather (I:1) who is 
deceased. Therefore, to determine if the variant was de novo or paternally inherited in the carrier mother 
(II:2), we sequenced her three sisters (II:1, II:3 and II:4) as they all inherited the same X chromosome 
from their deceased father. The sisters did not carry the NAA10 variant indicating that the variant has 
occurred de novo on the X chromosome of the carrier mother (II:2).
Naa10 Tyr43Ser mutation modelling. Naa10 is the catalytic subunit of the NatA complex and 
is responsible for Nt-acetylation of approximately 40% of the human proteome. Previously described 
NAA10 variants identified in patients with non-syndromic developmental delay or Ogden syndrome 
were shown to have a reduced catalytic activity, while the mutation causing LMS resulted in a loss of 
Naa10 expression. Amino acid sequence alignment of Naa10 orthologues reveal that Tyr43 is highly 
conserved through evolution (Fig. 4A), suggesting that Tyr43 is important for Naa10 function. Previously 
we made a human Naa10 homology model based on the coordinates of S. pombe NatA22,23 which can be 
used to study the localization of any of the 150 first amino acids of hNaa10. As can be seen in Fig. 4B, 
Tyr43 is located in the beginning of β 2 in the core of the globular domain of Naa10. The side chain of 
Tyr43 is tightly packed between β 1, β 3 and α 3, with the hydroxyl group facing out towards the surface 
of the protein. The Naa10 homology model thus suggests that Tyr43 is a structurally important residue 
for hNaa10, and that a p.(Tyr43Ser) mutation could cause structural changes in Naa10 that either affect 
Naa10 enzymatic activity or stability.
In vitro analysis of Naa10 Tyr43Ser catalytic activity. In order to directly assess the catalytic 
activity of the Naa10 Tyr43Ser variant, we mutated plasmids coding for a His/MBP-hNaa10 fusion pro-
tein, expressed proteins in E. coli BL21 cells and purified hNaa10 WT and hNaa10 Tyr43Ser by affinity 
chromatography and size exclusion chromatography. As can be seen in Fig. 5A, the largest bulk of Naa10 
Tyr43Ser molecules elute in the void volume of the size exclusion chromatography column. This indicates 
that the protein aggregates in units larger than 200 kDa, most likely due to an alteration of the protein 
structure, or a reduced protein stability. Despite the large number of molecules eluting in the void vol-
ume, a smaller amount of Naa10 Tyr43Ser molecules also eluted as a monomer. Fractions of monomeric 
Naa10 Tyr43Ser and Naa10 WT were collected and used for enzymatic experiments. In order to obtain 
similar enzyme concentrations, fractions of Naa10 WT were diluted to the same protein concentration 
Figure 3. Validation and segregation analysis. (A) Sanger sequencing confirmed segregation of the NAA10 
variant with the phenotype and the de novo status of the variant in the carrier mother (II:2). *The maternal 
grandfather’s DNA was not available for analysis. However, sequencing of his unaffected daughters showed 
that they do not carry the NAA10 variant on their paternal X chromosome indicating that the grandfather 
was hemizygous for the reference allele. (B) The NAA10 NM_001256120.1 c.128A > C p.(Tyr43Ser) was 
validated by Sanger sequence analysis. The inverted triangle indicates the position of the mutated A > C base 
on the forward strand which results in the substitution of Tyr (Y) with Ser (S) at residue 43.
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as Naa10 Tyr43Ser, and the purity of the purified enzymes was analyzed by SDS-PAGE and Coomassie 
(Fig. 5B). Purified enzymes were mixed with Ac-CoA and synthetic oligopeptides representing known 
Naa10 and NatA substrates and product formation was measured in the linear phase of the reaction. In 
vitro enzymatic assays revealed a drastic reduction of catalytic activity for the Naa10 Tyr43Ser variant. 
As can be seen in Fig.  5C,D, the Naa10 Tyr43Ser variant is clearly catalytically impaired in vitro, with 
approximately an 85% reduction in catalytic activity for both the Naa10 substrates EEEI and DDDI.
Analysis of Naa10 Tyr43Ser stability. In order to further assess the stability of the Naa10 Tyr43Ser 
variant we expressed V5-tagged hNaa10 WT and hNaa10 Tyr43Ser in HeLa cells and performed 
cycloheximide-chase experiments. As can be seen from Fig. 5E,F, the hNaa10 Tyr43Ser variant is clearly 
less stable compared to the hNaa10 WT. 2 hours after cycloheximide treatment, the average amount of 
Naa10 WT molecules present was 67.9 ± 18% relative to the amount of Naa10 molecules before treat-
ment, in comparison to 17.8 ± 8.4% for the hNaa10 Tyr43Ser variant. Altogether our functional analyses 
reveal a significant functional impairment of the Naa10 Tyr43Ser variant both in vitro and in cellulo.
Discussion
We report a novel X-linked recessive intellectual disability syndrome affecting two brothers in a 
non-consanguineous Irish family. The disorder is characterised by intellectual disability, dysmorphic 
features, hypotonia, scoliosis and long QT. Exome sequencing identified a missense variant in NAA10 
(c.128 A > C; p.(Tyr43Ser)) as the cause of this syndrome. The affected brothers are hemizygous and 
inherited the variant from their carrier mother (II:2), who is also mildly affected. Sanger sequencing con-
firmed that the NAA10 variant occurred de novo in the carrier mother who had normal X-inactivation 
in blood.
One interesting observation in our study is that the two brothers have remarkable phenotypic differ-
ences despite having the same mutation; one boy is more intellectually impaired while the other is more 
physically disabled. Why ? Intra-familial variability amongst males with X-linked recessive mutations is 
not common but has previously been reported. Laperuta and colleagues reported marked intra-familial 
clinical variability in five male relatives with X-linked mental retardation due to ARX duplication24. 
Lynch and colleagues described two brothers with a mutation in the X-linked intellectual disability gene 
Figure 4. Naa10 homology model and sequence alignment. (A) Amino acid sequence alignment of Naa10 
orthologues showing that Tyr43 is highly conserved through evolution. Sequences were gathered from 
the NCBI gene database and the sequence alignment was performed using clustalX. (B) Naa10 homology 
model showing Tyr43 in pink, and Ac-CoA in yellow. Tyr43 is located in the beginning of β 2 in the core of 
the globular domain of Naa10. The side chain of Tyr43 is tightly packed between β 1, β 3 and α 3, with the 
hydroxyl group facing out towards the surface of the protein.
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UPF3B who have variable degrees of developmental delay and notable differences in their spectrum of 
clinical features25. In relation to NAA10, there were significant differences in disease severity and progres-
sion amongst the nine males with LMS14. A number of factors can influence the phenotype and disease 
penetrance within a family, including gender, age of onset, modifier genes, chance/environmental effects 
and variations in the ‘rescue’ levels of nonsense-mediated decay (NMD). Gender and age of onset are not 
relevant in our case as both affected individuals are male and onset was from birth. It is also unlikely that 
the mutant protein in these patients undergoes NMD as the missense mutation affects protein structure 
and activity but does not produce a truncated protein. The exact reason for the variability between these 
Figure 5. Functional analysis of the hNaa10 Tyr43Ser variant. (A) Elution profile from a Superdex200 
size exclusion chromatography column. Proteins were expressed in E. coli BL21 cells and purified by 
affinity chromatography and size exclusion chromatography. (B) Fractions of monomeric Naa10 WT and 
Tyr43Ser were collected and the protein concentrations adjusted to equal protein concentrations. In order 
to assess the purity of the two purified enzymes, samples was analysed by SDS-PAGE and Coomassie. 
(C) Time-dependent NAT assay. Naa10 WT or Tyr43Ser was incubated with 300 μ M Ac-CoA and 300 μ M 
oligopeptides. The reaction was stopped at different time points by the addition of quenching buffer (3.2 M 
guanidinium-HCl, 100 mM sodium phosphate dibasic pH 6.8), and product formation was measured 
indirectly by the DTNB assay. (D) Naa10 NAT activity towards the Naa10 substrates EEEI and DDDI and 
the NatA substrate SESS. Naa10 Tyr43Ser is clearly catalytically impaired. (E) In order to study the stability 
of hNaa10 WT and hNaa10 Tyr43Ser in cellulo, hNaa10-WT-V5 and hNaa10-Tyr43Ser-V5 were expressed in 
HeLa cells. After two days of growth, cells were treated with 50 μ g/ml cycloheximide and the amount of V5-
tagged Naa10 present in the sample was measured in the following 6 hours. (F) Stability curves illustrating 
the levels of Naa10-V5 present in cells 0–6 hours following cycloheximide treatment. The stability assay 
shown is representative of six independent experiments.
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two brothers is unknown but may relate to modifier effects of variants in another gene and non-genetic 
factors.
Mutations in NAA10 have previously been associated with Ogden syndrome, LMS and non-syndromic 
developmental delay which are believed to be allelic disorders13–15. We now expand the NAA10 clinical 
spectrum to include a syndromic developmental delay disorder with long QT. Examination of the clin-
ical features associated with all four NAA10-related disorders suggests a possible genotype-phenotype 
correlation (Fig. 6 and Table 2). To date, all patients with NAA10 mutations show four common clinical 
features regardless of their syndrome; developmental delay (ranging from mild to severe), hypotonia, 
scoliosis and recurrent infections. So far, only patients with mutations in exons 2-6 (all those except 
patients with LMS) have experienced cardiac arrhythmias. Of note, all of the arrhythmia-related muta-
tions are located within the N-acetyl transferase domain of NAA10. Conversely, the LMS mutation which 
does not cause an arrhythmia is located outside of the N-acetyl transferase domain. This observation 
hints at a possible interaction between the NAA10 N-acetyl transferase domain and a known or novel 
arrhythmia gene. Alternatively, the reduced N-acetyl transferase activity of the mutant Naa10 enzymes 
may have a downstream effect on the regulation of an arrhythmia gene or protein. Further studies look-
ing at differential gene expression may help to decipher the basis for the cardiac arrhythmias in these 
patients.
As Naa10 is thought to acetylate over 8,000 different proteins, each disease mutation may affect the 
acetylation of different sets of substrates, resulting in different phenotypic features. Furthermore, one or 
more of the proposed lysine acetyltransferase (KAT) mediated activities or acetyltransferase independ-
ent functions of Naa10 may be affected26. Our functional studies revealed both a reduced stability and 
catalytic activity of the Naa10 Tyr43Ser variant. Naa10 Tyr43Ser had an approximately 85% reduction 
in catalytic activity compared to hNaa10 WT. In comparison, a 20-75% (dependent on the substrate oli-
gopeptide tested) reduction in catalytic activity was measured for the hNaa10 Ser37Pro variant causing 
OS, and an approximately 15% reduction in catalytic activity measured for the hNaa10 R116W variant 
causing NSDD in a 6 year old boy. Given the clinical features in the family reported in this study, it is 
surprising that Naa10 Tyr43Ser results in a more severe impairment in catalytic activity compared to the 
Ogden syndrome mutant Naa10 Ser37Pro which is lethal. Furthermore, Naa10 Tyr43Ser is unstable as 
compared to Naa10 wildtype, a feature not observed for Naa10 Ser37Pro23,27. It was previously suggested 
that the remaining catalytic activity of Naa10 variants could correlate with the severity of the phenotypes 
observed in each patient15. However, the present study shows that the relation between Naa10 mutations 
and disease phenotypes is more complex and that the in vitro catalytic activity in itself is not always 
sufficient in explaining phenotypes observed in patients.
There are a number of potential reasons that could account for these apparently contradicting obser-
vations. Firstly, the actual in vivo activity of Naa10 Tyr43Ser could be higher than that of Naa10 Ser37Pro 
(due to stabilizing partners or otherwise) and the in vivo Nt-acetylome is only modestly affected in Naa10 
Tyr43Ser cells. Secondly, Ogden syndrome may be caused by Nt-acetylation defects plus additional not 
yet elucidated non-NAT mediated effects. In contrast, Naa10 Tyr43Ser cells may only be defective in 
their Nt-acetylation. Thirdly, genetic background and proteome profile variation may modulate the 
Nt-acetylation capacity of the individual and cause differences in the impact of Nt-acetylation defects. 
For example, individual differences in the expression of Naa11 (ARD2), a functional Naa10 paralogue28, 
could have a significant impact on NatA-mediated Nt-acetylation. Lastly, the NAA10 gene has 16 tran-
scripts (Ensembl) of various lengths and starting positions. Therefore, depending on the location of a 
mutation, it may impact all or only a subset of NAA10 transcripts, which could influence the severity of 
the resulting phenotype.
Figure 6. Schematic outlining the genotype-phenotype correlation. The location of each reported NAA10 
variant associated with a specific syndrome is indicated above the schematic of the NAA10 gene (8 exons). 
The annotated domains and interaction sites are noted below the gene. The presence of a particular clinical 
feature is indicated by a green bar.
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The NAA10 variants causing non-syndromic developmental delay are de novo while the variants 
causing Ogden syndrome, LMS and syndromic development delay (current study) were inherited from 
carrier mothers. With Ogden syndrome, the carrier mothers have significantly skewed patterns of 
X-inactivation (90–100 %) biased against the X chromosome carrying the mutation, thereby protecting 
them from phenotypic expressivity23. With LMS, the heterozygous female carriers have mild manifesta-
tions such as abnormal ears and syndactyly which are milder versions of features present in the affected 
males14. While X-inactivation was not analysed in the carrier females, it was suggested that these mild 
features could be due to reduced expressivity or X-chromosome skewing with preferential inactivation 
of the wild-type allele14. In the current study, the carrier mother has mild manifestations of the disorder 
in her sons including long QT and mild intellectual disability. A normal non-skewed X-inactivation 
pattern was observed in blood. Therefore, the mild features in the mother may be due to tissue-specific 
X-chromosome skewing or a dominant-negative effect of the mutant protein.
Clinical feature OS LMS NSDD Current
Developmental delay + + + + + + + + + 
Delayed motor development + + + —
Aged appearance + — — —
Microcephaly — — + —
Craniofacial abnormalities + — + —
Dysmorphic features + + + + + + + + 
Fontanels large — delayed closure —
Microretrognathia + — — —
Eyes prominent small or absent deep set normal
Hypertelorism + * — — + *
Truncal hypotonia + * + + + 
Hypertonia + — + —
Abnormal ears large over-folded upper pinnae large low set, crumpled
Flared nares + — — —
Abnormal palate narrow high arched high arched —
Pectus abnormalities excavatum excavatum carinatum —
Clinodactyly + + — —
Foot and toe abnormalities + + + + *
Small hands and feet — — + + 
Scoliosis + + + + + + + 
Renal abnormalities — + * — —
Cardiac arrhythmia + — + + 
Cardiac malformations ASD, PPS, CM, DA + PAS, ASD —
Cryptorchidism + — — —
Hernia Umb, Ing diaphragmatic* — umbilical
Little subcutaneous fat + — — —
Eczema + — — —
Recurrent infections + + + + 
Otitis media + + (chronic) — + (recurrent)
Seizures + * + * — + *
Lethality + — — —
Behavioural issues n/a + + + + + —
X chr skewing in females + + + + n/a —
Table 2.  Comparison of clinical features present in NAA10-associated disorders. Clinical features 
reported in all four NAA10-associated disorders are highlighted in bold. Features are denoted as present 
(+ mild, + + moderate, + ++ severe) or absent (–). Features present in some but not all patients with that 
particular disorder are denoted by the * symbol. Abbreviations: ASD: atrial septal defect; CM: cardiomegaly; 
DA: ductus arteriosus; Ing: inguinal; LS: Lenz microphthalmia; NSDD: non-syndromic developmental delay; 
OS: Ogden syndrome; PAS: pulmonary artery stenosis; PPS: peripheral pulmonary stenosis; Umb: umbilical.
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In summary, we report a novel missense variant in NAA10 as the cause of a new developmental delay 
syndrome which includes long QT. Our findings suggest that it is important to consider cardiac screening 
in both male and female patients who have pathogenic NAA10 mutations as even female carriers can 
have long QT. As is the case in our study, female carriers may have a predominantly cardiac phenotype 
and it may not be obvious that their cardiac problems are part of a syndrome. Therefore, consideration 
should be given to the addition of the NAA10 gene to Next-Generation Sequencing-based cardiac panels. 
To date, NAA10 has been implicated in a variety of overlapping yet distinct disorders – all of which are 
likely caused by impaired Nt-acetylation of NatA targets. It is possible that each disease mutation has dif-
ferent effects on the acetylation of NatA’s 8,000 protein targets, thereby accounting for the diverse range 
of clinical features associated with this gene. Further investigation into the spectrum of downstream 
acetylation defects in each syndrome may help to understand how variation in a single gene can give 
rise to such complex phenotypes.
Materials and Methods
Consent and ethics. Written informed consent, including consent to publish patient photographs, 
was obtained from the patients. The study protocol was approved by the ethics committee of Temple 
Street Children’s University Hospital (Dublin, Ireland). All experiments were performed in accordance 
with the approved guidelines and regulations.
Whole exome sequencing. Genomic DNA was isolated from blood lymphocytes according to 
standard procedures. DNA from one affected child (III:2) was selected for whole exome sequencing 
(Eurofins Genomics, Germany). The exonic DNA was enriched with the SureSelectv5 50 Mb Human All 
Exon Kit (Agilent Technologies, Santa Clara), and sequenced on an Illumina HiSeq at Eurofins Genomics 
(Ebersberg, Germany). The 100 bp paired-end reads were aligned to the hg19 human reference genome 
with the Burrows-Wheeler Alignment tool 0.5.729. Reads of inadequate sequence quality and potential 
PCR duplicates were discarded. The quality scores for the aligned reads were recalibrated using GATK30. 
Regions containing clusters of SNPs were identified and the reads in these regions were realigned using 
GATK. Variants and indels were identified using SAMtools and annotated using ANNOVAR31. Assuming 
an X-linked recessive model, we prioritised variants that were (i) absent or present with a frequency < 1% 
in dbSNP142, 1000 Genomes and the NHLBI Exome Variant Server database (http://evs.gs.washington.
edu/EVS/), (ii) coding (nonsense, missense, splice site or indel), (iii) on the X chromosome (X-specific), 
(iv) hemizygous, (v) absent in our 60 control exomes, (vi) previously implicated in developmental delay/
intellectual disability and (vii) segregated with the phenotype (Table S2).
Validation and segregation analysis. Candidate variants were validated and segregation tested by 
bi-directional Sanger sequencing of DNA from all available family members (Table S3). As DNA was 
unavailable from the deceased father (I:1) of patient II:2, we confirmed the de novo status of the can-
didate NAA10 variant by testing the sisters of patient II:2, all of whom would have inherited the same 
paternal X chromosome as the patient. If the sisters carried the variant it would indicate paternal inher-
itance. Conversely, absence of the variant from the X chromosome of the sisters would confirm that 
the maternal grandfather (I:1) did not carry the candidate variant on his X chromosome and, hence, 
it is de novo in patient II:2. Patient II:2 and an unaffected sibling were genotyped for 964,193 Single 
Nucleotide Polymorphisms (SNPs) on the Illumina OmniExpress Exome array according to standard 
protocols (AROS Applied biotechnology, Aarhus, Denmark). Family structure was confirmed using 
identity-by-state calculations in PLINK32. The identified de novo variant in NAA10 was submitted to the 
LOVD gene variant database at http://www.lovd.nl/NAA10.
Plasmid construction and protein purification. Plasmids encoding His/MBP-Naa10 p.Tyr43Ser, 
and V5-Naa10 p.Tyr43Ser were created by site-directed mutagenesis (QuikChange® Multi Site-Directed 
Mutagenesis kit) according to the manufacturer’s protocol. A pETM41 vector (from G. Stier, EMBL, 
Heidelberg, Germany) encoding Naa10 WT with Maltose Binding Protein/His-fusion as a fusion tag33, 
and a pcDNA3.1 mammalian expression vector (Life technologies) encoding Naa10 WT with a V5 fusion 
tag12 were used as a template for the site-directed mutagenesis. Primers used for the mutagenesis were 
hNAA10 A128C f: CCTGGCCCCAGCTCTCTTCCATTGCTGAGGACGAGAATGGG and hNAA10 
A128C r: CCCATTCTCGTCCTCAGCAATGGAAGAGAGCTGGGGCCAGG. Mutations were verified 
by Sanger sequencing, and plasmids were transformed into E. coli BL21 Star (DE3) by heat shock trans-
formation. E. coli BL21 cells were grown in 200 mL cell cultures at 37 °C to an OD600nm of 0.6, and 
then cooled down to 18 °C before starting protein expression by the addition of IPTG to a total con-
centration of 500 μ M. After 14 hours of incubation, cell cultures were harvested and the pellet stored at 
− 80 °C. Pellets were dissolved in lysis buffer (50 mM Tris-HCl (pH 7.4), 1 M NaCl, 1 mM DTT, and one 
tablet of EDTA-free protease inhibitor per 50 mL) and cells lysed by 6 × 30 seconds of sonication on ice. 
Recombinant MBP-hNaa10 was purified by Immobilized Affinity Chromatography (1ml HisTrap HP, 
GE Healthcare) and Size Exclusion Chromatography (Superdex 200 10/300, GE Healthcare). Buffers 
used for purification were: IMAC wash buffer (50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 1 mM DTT, 
25 mM Imidazole), IMAC elution buffer (50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 1 mM DTT, 300 mM 
Imidazole) and Size exclusion chromatography buffer (50 mM HEPES (pH 7.5), 300 mM NaCl, 1 mM 
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DTT). Fractions were analyzed by SDS-PAGE and protein concentration was determined by both A280 
measurements (Nanodrop1000) and Bradford assay (BioRad).
In Vitro Acetylation Assays. As previously described, a colorimetric acetylation assay34,35 and a quan-
titative HPLC assay36 were used to measure the catalytic activity of the Naa10 variants. Briefly for the col-
orimetric assay, the thiol present in the enzymatic product, CoA, cleaves 5,5′ -dithiobis-(2-nitrobenzoic 
acid) (DTNB) and produces 2-nitro-5-thiobenzoate (NTB–), which is quantified by monitoring the 
absorbance at 412 nm. Purified enzymes were mixed with different substrate peptides and Ac-CoA 
in acetylation buffer (50 mM HEPES pH 7.5, 100 mM NaCl , and 0.2 mM EDTA), and reactions were 
quenched with quenching buffer (3.2 M guanidinium-HCl, 100 mM sodium phosphate dibasic pH 6.8). 
As a negative control, reactions without enzyme were incubated at 37 °C, and enzymes were added to the 
reaction after quenching. To measure CoA production, DTNB (2 mM final, dissolved in 100 mM sodium 
phosphate dibasic pH 6.8 and 10 mM EDTA) was added to the quenched reaction and the absorbance at 
412 nm was measured. Background absorbance was determined in the negative controls, and subtracted 
from the absorbance determined in each individual reaction. Thiophenolate production was quantified 
assuming ε = 13.7 × 103 M–1 cm–1.
In the quantitative HPLC acetylation assay, enzymes were mixed with substrate peptides and Ac-CoA 
in reaction buffer (50 mM HEPES pH 7.5, 100 mM NaCl and 0.2 mM EDTA), incubated at 37 °C and 
stopped by the addition of 10% Trifluoroacetic acid (TFA). Product formation was quantified with 
RP-HPLC as described previously36. In the quantitative acetylation assay the following oligopeptides 
(Biogenes) were used: EEEI ([H]EEEIAAL RWGRPVGRRRRPVRVYP[OH]) representing γ -actin, 
DDDI ([H]DDDIAAL RWGRPVGRRRRPVRVYP[OH]) representing β -actin and SESS ([H]SESSSKS 
RWGRPVGRRRRPVRVYP[OH]), representing high-mobility group protein A1. Product formation was 
measured in the linear phase of the reaction.
Protein stability analysis of hNaa10-Tyr43Ser-V5 by cycloheximide chase assay. HeLa cells 
were plated on 6 well plates (Ø 34.8 mm) 16 h before transfection. Cells at 80% confluency were transiently 
transfected with 2.6 μ g hNaa10-Tyr43Ser-V5 and hNaa10-WT-V5, respectively by using X-tremeGENE 
9 DNA transfection reagent (Roche). After 24 h medium was replaced. 48 h after transfection 50 μ g/ml 
cycloheximide was added to the cells. For samples of time point 0 h no cycloheximide was added to 
the cells before harvesting. 2 h, 4 h and 6 h after adding cycloheximide, cells were harvested in 1400 μ l 
cold PBS (pH 7.4) by using a cell scraper. Cells were spun down at 4 °C and 1000 × g for 5 minutes. 
Supernatant was removed before cells were resuspended in 1 ml of cold PBS. Cells were again spun 
down under same conditions. After removing of supernatant, cells were lysed in 40 μ l of IPH lysis buffer 
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40), containing complete EDTA free 
protease inhibitor (Roche), on ice for 20 minutes. After centrifugation at 4 °C and 17000 x g for 8 min-
utes, supernatant was transferred into a new reaction tube and Laemmli loading buffer, containing SDS, 
was added. The V5-tagged hNaa10 protein was detected using a standard Western blotting procedure. 
Therefore, 10 μ l of each sample was resolved on a 12% SDS-PAGE gel, transferred onto a nitrocellulose 
membrane (Amersham Protran 0.2 NC) and after blocking with 5% non-fat dry-milk (Regilait), incu-
bated with anti-V5-tag antibody (Invitrogen, R960-25), anti-β -Tubulin antibody (Sigma Aldrich, T5293), 
anti-hNaa10 antibody (anti-hARD1) and anti-hNaa15 antibody (anti-NATH)12. The blot was visualized 
using horseradish peroxidase-conjugated anti-mouse IgG antibody and anti-rabbit IgG antibody (GE 
Healthcare) respectively and SuperSignal West Pico Chemiluminescent Substrate Kit (Thermo Scientific). 
Signals were detected by using ChemiDocTM XRS + system of Bio-RAD. Normalization of the signals was 
done with ImageLabTM system 5 of Bio-RAD.
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